Clinical trial
A Phase 2, Multicentre, Randomised, Double-masked, Placebo-controlled, Parallel-group, Dose-range Finding Study, to Assess the Efficacy and Safety of Oral STL303 in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07606365 is registered in ClinicalTrials.gov with Sitala Bio LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicentre, Randomised, Double-masked, Placebo-controlled, Parallel-group, Dose-range Finding Study, to Assess the Efficacy and Safety of Oral STL303 in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
- Lead sponsor
- Sitala Bio LTD
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 11, 2026
- Completion date
- August 31, 2029
- Enrollment
- 300 (estimated)
- Sites
- 56
Conditions
As the registry lists them; a condition with its own page is linked.